Latest Renal cell carcinoma Stories
NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Pfizer Inc.
DURHAM, N.C., Sept. 24 /PRNewswire/ -- Argos Therapeutics today announced that results from its Arcelis(TM) immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct.
TUEBINGEN, Germany, September 21, 2010 /PRNewswire/ -- - New Investment Allows immatics to Perform Pivotal Study With its Lead Vaccine IMA901 in Patients With Renal Cell Carcinoma (RCC) - Study to Start in 2010 - IMA901 Phase II Trial has Shown the Potential to Confer an Overall Survival Benefit - Financing Supported by Both New and Existing Investors immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active...
The unprecedented growth and promise of using thermal ablation to target and kill cancer is the subject of the Journal of Vascular and Interventional Radiology's August supplement, "Thermal Ablation 2010: At the Crossroads of Past Success, Current Goals and Future Technology."
NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc.
ARDEN HILLS, Minn., July 9 /PRNewswire/ -- Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, today announced that Vanderbilt University Medical Center in Nashville, Tenn., has treated the first patient to be included in its new patient registry.
EAST HANOVER, N.J., July 1 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results of a Phase III study show AfinitorÂ® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).
WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, robust 4.1 percent annual growth in the renal cell carcinoma drug market will be driven primarily by the uptake of GlaxoSmithKline's Votrient/Patorma, the launches of premium-priced emerging therapies and an increase in diagnosed incidence and treatment rates.
WAYNE, N.J. and EMERYVILLE, Calif., June 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
SALT LAKE CITY, June 9 /PRNewswire/ -- GE Healthcare, a unit of the General Electric Company (NYSE: GE), today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute (NCI), a federal research agency and part of the National Institutes of Health.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).